Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 14, 2021

SELL
$25.12 - $36.89 $1.04 Million - $1.53 Million
-41,577 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$27.44 - $73.84 $4.72 Million - $12.7 Million
-171,985 Reduced 80.53%
41,577 $1.31 Million
Q3 2019

Nov 13, 2019

BUY
$34.47 - $47.53 $998,078 - $1.38 Million
28,955 Added 15.68%
213,562 $7.83 Million
Q1 2019

May 14, 2019

BUY
$40.11 - $53.57 $1.7 Million - $2.27 Million
42,318 Added 29.74%
184,607 $7.41 Million
Q4 2018

Feb 13, 2019

SELL
$36.99 - $59.11 $1.74 Million - $2.78 Million
-46,998 Reduced 24.83%
142,289 $6.55 Million
Q1 2018

May 14, 2018

BUY
$65.94 - $80.76 $12.5 Million - $15.3 Million
189,287 New
189,287 $13.7 Million

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $164M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Tekla Capital Management LLC Portfolio

Follow Tekla Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.